Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951145 | 0.87 | HRH3 (0.48) | HRH3NPY5RHTR2AHTR2CAHR | |
| SCHEMBL18896613 | 0.85 | HRH3 (0.53) | HRH3NPY5RAHRPDK2TSHR | |
| SCHEMBL17779118 | 0.83 | HRH3 (0.68) | HRH3NPY5RKDM4EHTR2BSIGMAR1 | |
| SCHEMBL17779117 | 0.83 | HRH3 (0.59) | HRH3NPY5RHTR2BSIGMAR1HTR2A | |
| SCHEMBL17778814 | 0.82 | HRH3 (0.55) | HRH3NPY5RSIGMAR1TSHR | |
| SCHEMBL17778816 | 0.82 | HRH3 (0.55) | HRH3NPY5RSIGMAR1TSHRCASP6 | |
| SCHEMBL30817706 | 0.82 | PDE7A (0.54) | HRH3NPY5RAHRPDK2TSHR | |
| SCHEMBL11640043 | 0.82 | PDE7A (0.54) | HRH3NPY5RAHRPDK2TSHR | |
| SCHEMBL12568543 | 0.81 | HRH3 (0.41) | HRH3NPY5RKDM4EGLAHTR2B | |
| SCHEMBL17778813 | 0.81 | SIGMAR1 (0.56) | HRH3NPY5RHTR2BSIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160318870-A1 | RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318870-A1 | RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015035278-A1 | RORγ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7803807-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7803807-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7687514-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687514-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MSD K.K. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MSD K.K. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-7384930-B2 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| EP-1795527-A1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | HRH3 3778/4885NPY5R 3509/4885KDM4E 2327/4885 |
| US-20160318870-A1 | RORy MODULATORS | RORB, RORC, RORA | HRH3 612/4885NPY5R 153/4885KDM4E 2509/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | HRH3 253/4885NPY5R 2188/4885KDM4E 4007/4885 |
| US-20100048600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | NPY4R, NPY5R, NPY1R | HRH3 42/4885NPY5R 2/4885KDM4E 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.